CLINICAL TRIAL: LONG-TERM RHIGF-I TREATMENT IN CHILDREN WITH SHORT STATURE DUE T

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是评价一种名为重组人胰岛素样生长因子I（rhIGF-I）的实验性药物治疗矮小症的安全性和有效性。该研究的目的是观察rhIGF-I每天注射两次是否会改善生长激素不敏感综合征儿童的生长，并测试rhIGF-I的长期安全性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to evaluate the safety and efficacy of an experimental drug named recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of short stature. The purpose of the study is to see if injections of rhIGF-I two times daily will cause improved growth in children with growth hormone insensitivity syndrome, and to test the long-term safety of rhIGF-I.